The combination of aflibercept and OPT-302, a blocker of VEGF-C and VEGF-D, showed potential for improved visual and anatomic outcomes in patients with diabetic macular edema.
The outcomes of phase 1b and 2a trials, presented at the virtual American Academy of Ophthalmology annual meeting, look promising and may fulfill an unmet need for those patients who do not respond well to anti-VEGF therapy, David S. Boyer, MD, said.
“Almost 40% of DME patients do extremely well with anti-VEGFs, but about 35% gain less than four letters. Combination therapy might improve (Read more...)
Uncategorized